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Chronic rhinosinusitis with (CRSwNP) and without nasal polyps (CRSsNP) should be re-
garded as distinct clinical entities based on differential inflammatory mediator and remodel-
ing profiles. Activin A, a member of the TGF-β superfamily, plays an important role in
inflammation and remodeling in the lower airways, although its expression and release in
the upper airways remain undescribed.
Objective
To investigate the expression of activin A and its inhibitor follistatin in nasal tissue samples
from CRSsNP and CRSwNP patients, and to monitor the spontaneous release of these
molecules in a human mucosal model.
Methods
Protein levels were determined using ELISA for activin A, follistatin, TGF-β1 and indicator
proteins (IL-5, ECP, IFNγ) in 13 CRSsNP, 23 CRSwNP, and 10 control samples. The spon-
taneous release rate and the release ratios of activin A, follistatin and TGF-β1 were deter-
mined in 9 CRSsNP and 7 CRSwNP tissue fragments cultured ex-vivo. The induction of
activin A and TGF-β1 by one another was studied in 7 CRSsNP tissue fragments cultured
ex-vivo.
Results
Significantly higher concentrations of activin A, follistatin, TGF-β1, and IFNγ were observed
in CRSsNP compared with CRSwNP samples, whereas the concentrations of IL-5 and
ECP were significantly lower. Follistatin was positively and linearly correlated with activin A
in CRSsNP and CRSwNP. Activin A, follistatin and TGF-β1 were all spontaneously
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released by the samples, although the relative ratios released by tissue fragments from
CRSsNP and CRSwNP samples were significantly different, with a higher follistatin/activin
A-ratio and a follistatin/TGFß1-ratio (with less overall TGF-β1) in CRSwNP than in
CRSsNP. Furthermore, TGF-β1 enhanced activin A secretion in CRSsNP tissue fragments
cultured ex-vivo.
Conclusion
The differences in tissue concentrations and spontaneous release rates for activin A and
follistatin in different CRS samples support the hypothesis that CRSsNP and CRSwNP are
two distinct disease entities with respect to remodeling patterns.
Introduction
Chronic rhinosinusitis (CRS) is a common health problem with an overall prevalence of 10.9%
in Europe by EP(3)OS criteria [1], and it is currently classified into two major subgroups:
chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal
polyps (CRSsNP) [2]. Evidence suggests that CRSwNP and CRSsNP should be regarded as dis-
tinct clinical entities, based on different inflammatory mediator and remodeling profiles [3–5].
CRSwNP is characterized by dysregulation of regulatory T (Treg) cells and inflammatory cells,
coincident with intense edematous stroma, albumin deposition and pseudocyst formation; by
contrast, CRSsNP is characterized by normal Treg cell number and migration capacity and sig-
nificantly less severe inflammatory mucosal reactions, coincident with fibrosis, basement mem-
brane thickening and goblet cell hyperplasia [6, 7]. However, the exact mechanism of
inflammation and remodeling in CRS has not been elucidated.
Recently, it has been found that the transforming growth factor beta (TGF-β) superfamily
plays an important pathophysiological function in airway diseases, including CRS [7]. The
TGF-β superfamily consists of more than 33 members, all of which have a similar prodomain
fold [8], and they control numerous physiological processes, including wound healing, tissue
regeneration and immunity [9]. TGF-β1, an important member of this superfamily, and its sig-
naling transduction pathways are up-regulated in CRSsNP and down-regulated in CRSwNP
[10]. Recent evidence suggests that TGF-β1 is involved in the very early events of respiratory
disease as well as in late persistent disease, both in inflammatory and remodeling processes
[11]. Activin A, another important member of the TGF-ß superfamily, utilizes similar signaling
transduction pathways as TGF-β1, including Smad-dependent and Smad-independent path-
ways [9]. Generally, TGF-β1 is an activator of tissue fibrosis and a potent inhibitor of inflam-
mation. Thus, it is possible that activin A also functions to activate tissue repair programs
while modulating the inflammatory response.
A growing body of evidence suggests that the deregulation of activin signaling contributes
to pathologic conditions such as chronic inflammation, fibrosis and carcinogenesis [12–15].
Follistatin, also known as activin-binding protein, is an endogenously produced protein that
binds activin A with high affinity and inhibits its bioactivity. The primary function of follistatin
is the binding and bioneutralization of members of the TGF-β superfamily, and activin A in
particular [12]. Moreover, in lower airway disease, both activin A and TGF-β1 have been impli-
cated in airway inflammation and remodeling, and their signaling pathways are activated upon
allergen provocation in asthma [14]. Changes in the balance of activin A and follistatin –
which may be a determinant of the severity of allergic inflammation or tissue phenotypic
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shift – have also been observed in asthma [15]. We found that TGF-β1 serves as an important
switch for different inflammatory and remodeling patterns in sinus disease [7, 10]. In addition
to detecting several important inflammatory and remodeling cytokines, such as IFNγ, IL-5,
and eosinophil cationic protein (ECP), the aim of the present study was to analyze the expres-
sion and spontaneous release of activin A and follistatin, as well as the interaction between acti-
vin A and TGF-β1 in CRS. The study was also designed to test whether activin A expression is
increased in CRSsNP and is associated with increased TGF-β1 levels, as well as whether the
production of follistatin may be involved in the anti-fibrotic milieu in CRSwNP, consistent
with the hypothesis that CRSsNP and CRSwNP are two distinct disease entities.
Materials and Methods
Patients and sample collection
The study subjects were selected at the Department of Otorhinolaryngology of Ghent Universi-
ty Hospital, Belgium. The diagnosis of sinus disease was carried out according to European Po-
sition Paper on Rhinosinusitis and Nasal Polyps guidelines (EPOS) [2], which are based on
history, clinical examination, nasal endoscopy, and sinus CT scans. General exclusion criteria
were based on the EPOS definition for research. None of the subjects received anti-histamines,
anti-leukotrienes, oral or intranasal decongestants, or intranasal anti-cholinergics during the 2
weeks prior to surgery. A washout period was maintained for 4 weeks before surgery for oral
and topical corticosteroids and antibiotics. Females who were pregnant or breast-feeding were
excluded from the study. The ethics committee of the Ghent University Hospital approved the
study, and all patients gave their written informed consent prior to inclusion in the study.Sam-
ples from patients with CRSsNP (n = 13; median age, 39 years; range, 20–81 years; 6 women, 7
men) and CRSwNP (n = 23; median age, 49 years; range, 19–71 years; 10 women, 13 men)
were obtained during functional endoscopic sinus surgical procedures. Inferior turbinate sam-
ples from patients without sinus disease undergoing septoplasty or rhinoseptoplasty were col-
lected as controls (n = 10; median age, 29 years; range, 18–60 years; 4 women, 6 men). For
CRSsNP, the tissue samples were collected from ethmoidal mucosa. For CRSwNP, samples of
ethmoidal polyp tissue were used. All patients underwent a skin prick test (SPTs) against the
European standard panel of 14 inhalant allergens. Negative and positive controls (10 mg/mL
histamine solution) were included with each SPT. None of the control subjects had a history of
asthma or a positive SPT. One of the patients with CRSsNP and 7 of the patients with CRSwNP
had a positive SPT. In the CRSwNP group, 5 of the 23 patients had a history of asthma, and 2
patients reported aspirin intolerance (Table 1).
The nasal tissues collected during surgery were immediately transported to the laboratory,
snap frozen in liquid nitrogen, and stored at -80°C until analysis by ELISA. Remaining tissues
from specific subjects were used for ex vivo tissue stimulation experiments.
Measurements of mediators in tissue homogenates
The frozen tissues were thawed, weighed, homogenized and centrifuged as described previously
[16]. The samples were then assayed for activin A, follistatin, total TGF-β1, and other cytokines
(IFNγ, IL-5, ECP) using commercially available ELISA kits from R&D Systems (Minneapolis,
Minnesota, USA) with the appropriate dilution factor and according to kit instructions. All
data were expressed as picogram per milliliter. For TGF-β1, acid was added during the ELISA
procedure, resulting in physicochemical activation of latent TGF-β1. Total TGF-β1 concentra-
tions were reported, including both active and latent forms.
Activin A and Follistatin in CRS
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Immunofluorescence assay
The localization of Activin A and follistatin in nasal tissue was assessed using immunofluores-
cence microscopy. Cryo-sections (5μm) of nasal tissue were firstly incubated with 0.2% Triton
X-100 at room temperature (RT) for 10 min, were then blocked with 0.5% bovine serum albu-
min for 30 min. The samples were incubated with anti-ActivinA (7.5μg/ml) or anti-follistatin
(7.5μg/ml) primary polyclonal goat antibodies (R&D) for 2 h at RT, washed, and incubated
with the corresponding rabbit anti-goat IgG (R&D) (1:200) for 1 h at 37°C. The nuclei were la-
beled with 4,6-diamidino-2-phenylindole (DAPI), and the sections were visualized by
fluorescence microscopy.
Preparation and stimulation of human nasal tissue ex vivo
Among the patients included, 9 CRSsNP, 7 CRSwNP patients and 7 controls without positive
SPT, asthma or aspirin intolerance, as well as less than 65 years old, were selected for ex-vivo
culture experiments. The nasal tissue explants were prepared as described previously [16, 17].
Briefly, the human nasal mucosa and submucosa were thoroughly fragmented in RPMI-1640
culture medium (Sigma-Aldrich, Bornem, Belgium) containing 2 mM l-glutamine (Invitrogen,
Merelbeke, Belgium), 50 IU/ml penicillin, 50 mg/ml streptomycin (Invitrogen) and 0.1% BSA
(Sigma-Aldrich). Tissue fragments were then weighed, resuspended at 0.04 g tissue/ml in cul-
ture medium and pre-incubated for 1 h at 37°C and 5% CO2. The tissue fragments were resus-
pended in the appropriate amount of culture medium, and 1 ml of the fragment suspension
was dispensed per well in a 12-well plate (BD Falcon, VWR, Leuven, Belgium). Due to in-
creased expression levels in CRSsNP, the CRSsNP fragment suspensions were selected and
stimulated with either culture medium (negative control) for 1 h, 4 h and 24 h or with TGF-β1
or Activin A (Sigma-Aldrich N.V./S.A, Bornem, Belgium) for 24 h. Supernatants were separat-
ed by centrifugation and stored immediately at -20°C until analysis by ELISA.
Quantification of mediators in the supernatants of stimulated tissue
fragments
The concentrations of activin A, follistatin, and TGF-β1 were measured in tissue supernatants
obtained after stimulation using ELISA kits from R&D Systems (Minneapolis, Minnesota,
USA), according to the manufacturer's instructions.
Table 1. Patient’s details.
Control CRSsNP CRSwNP P values
No. of patients 10 13 23
Age (y) median (range) 29(18–60) 39(20–81) 49(19–71) #
No. of female/male 4/6 6/7 10/13 0.957
Skin prick test–positive (n/N) 0/10 1/13 7/23 0.070*
Asthma in history (n/N) 0/10 0/13 5/23 0.087*
Aspirin intolerance (n/N) 0/10 0/13 2/23 0.711*
# p = 0.0097 (CRSwNP vs Control) was obtained by ANOVA. Constituent ratio was compared by crosstabs. Gender comparison was done by Chi-
square test
*Fisher exact test. P <0. 05 was considered statistically signiﬁcant.
doi:10.1371/journal.pone.0128564.t001
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Statistical analysis
Statistical analysis was performed using the MEDCALC version 13.1.2.0 software program
(Schoonjans F, Mariakerke, Belgium). Normal distributed data are expressed as mean values
(±SD), and for variables with a non-Gaussian distribution, values are expressed as median and
inter-quartile ranges (25th–75th percentile). Statistical analysis was performed by using the
Wilcoxon test (for paired comparisons). The Mann-Whitney U test was used for between-
group (unpaired) comparisons. Constituent ratio was compared by crosstabs. Linear correla-
tion analysis was performed between two variables of activin A, follistatin and TGF-β1 in each
group. Exact p values were reported. The significance level was set at α = 0.05.
Results
Protein expression in nasal tissue
Tissue homogenates were tested by ELISA. Activin A protein expression was significantly
higher in CRSsNP compared with CRSwNP (p = 0.024) and controls (p = 0.047). Significantly
increased expression of follistatin protein in CRSsNP relative to CRSwNP (p = 0.008) was ob-
served. Similarly, the expression of TGF-β1 protein was significantly higher in CRSsNP than in
CRSwNP (p = 0.003). A linear correlation analysis was carried out between these parameters,
which revealed that follistatin protein levels were positively correlated with activin A protein
levels in CRSsNP (r = 0.819, p = 0.001) and in CRSwNP (r = 0.532, p = 0.013) (Fig 1). Immuno-
fluorescence staining (Fig 1F) showed Activin A and follistatin were mainly expressed in the
cytoplasm of nasal epithelial cells. IFNγ protein expression was significantly higher and IL-5
and ECP expression was significantly lower in CRSsNP compared with CRSwNP (Fig 2).
Spontaneous release in nasal tissue fragments
Nasal tissue fragments from CRSsNP (n = 9) and CRSwNP (n = 7) were plated in RPMI with-
out stimulation. The supernatants were evaluated by ELISA at 1, 4, and 24 h (Fig 3). Compared
with the 1 h time point, the release of activin A, follistatin and TGF-β1 was significantly en-
hanced at 4 h (p<0.05) and 24 h (p<0.01) in CRSsNP and at 24 h (p<0.05) in CRSwNP. At
24 h, the release of activin A (p = 0.015) (Fig 3A) and follistatin (p = 0.005) (Fig 3B) was higher
in CRSwNP than in CRSsNP; in contrast, the release of TGF-β1 (p = 0.036) (Fig 3C) was lower
in CRSwNP than in CRSsNP.
Differential ratios of follistatin/activinA and follistatin/TGF-β1 in nasal
tissue and supernatants
To elucidate the relationship between follistatin, activin, and TGF-β1 in the nasal tissue sam-
ples and supernatants, the different ratios of follistatin/ActivinA and follistatin/TGF- β1 in
nasal tissue homogenates and supernatants at 24 h were calculated and compared (Fig 4). In
the tissue, the follistatin/activinA ratio was lower in CRSsNP than in the controls (p = 0.023)
but was similar in CRSsNP and CRSwNP (Fig 4A). In addition, the follistatin/TGF- β1 ratio
was lower in CRSsNP than in CRSwNP (p = 0.037) (Fig 4B). In the supernatants at 24 h, both
the follistatin/activinA (p = 0.032) (Fig 4C) and follistatin/TGF- β1 (p = 0.007) (Fig 4D) ratios
were lower in CRSsNP than in CRSwNP. An imbalance between pro-fibrotic (TGF- β1, activin
A) and anti-fibrotic (follistatin) mediators was apparent in CRSsNP and CRSwNP.
Activin A and Follistatin in CRS
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Fig 1. Protein expression and linear correlation (D, E) of activin A (A), Follistatin (B) and TGF-beta1 (C)
in nasal tissue from CRSsNP (n = 13), CRSwNP (n = 23) and Control patients (inferior turbinate)
(n = 10). The figures show that the expression of all three proteins (Activin A, Follistatin and TGF-ß1) were
higher in CRSsNP than in CRSwNP; Follistatin protein was positively correlated with activin A protein in
CRSsNP and in CRSwNP. Significance is indicated by P value. Immunofluorescence staining (F) showed
both Activin A (green fluorescence) and follistatin (red fluorescence) were mainly expressed in the cytoplasm
of nasal epithelial cells. ×630.
doi:10.1371/journal.pone.0128564.g001
Activin A and Follistatin in CRS
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TGF-β1 enhances activin A secretion in CRSsNP tissue fragments ex
vivo
To test the stimulatory effects of the autocrine factors TGF-β1 and activin A in CRSsNP tissue,
we examined how they influenced the secretion of one another in nasal tissue fragments (Fig
5). Compared with controls, activin A secretion was higher in CRSsNP under each condition
(p<0.05). Compared with 0 ng/ml, activin A secretion was enhanced by 10 ng/ml TGF-β1 in
both CRSsNP (n = 7) and control tissue fragments (n = 7) (p<0.05) (Fig 5A). However, TGF-
β1 secretion was not enhanced by activin A in the CRSsNP or control tissue fragments (Fig
5B).
Discussion
The results presented here suggest that, along with TGF-β1, activin A and follistatin are coop-
erative regulators of the remodeling processes during CRS, supporting the hypothesis that
CRSsNP and CRSwNP are two distinct disease entities. This idea is consistent with the signifi-
cantly higher protein concentrations of activin A, follistatin, TGF-β1, and IFNγ and the lower
concentrations of IL-5 and ECP in CRSsNP compared with CRSwNP tissue homogenates (Fig
6). Based on the different release patterns of activin A, follistatin and TGF-β1, an imbalance be-
tween pro-fibrotic (activin A, TGF-β1) and anti-fibrotic (follistatin) mediators was revealed,
which favors fibrosis in CRSsNP and edema in CRSwNP. Furthermore, the fact that TGF-β1
enhanced activin A secretion in CRSsNP tissue fragments indicates that TGF-β1 may potenti-
ate activin A secretion in CRSsNP. Overexpression of activin A and TGF-β1 has been associat-
ed with increased lung fibrosis and airway remodeling in the lung [12, 15]. Follistatin, which
can bind to and block the actions of activin A, has a beneficial role in attenuating fibrosis [18].
The increased expression of activin A during clinical and experimental asthma suggests that
this cytokine is involved in the pathogenesis of asthma [19]. Similarly, these data reveal differ-
ential regulation of activin A and follistatin in CRSsNP and CRSwNP, which could be relevant
to the pathogenesis of CRS.
The TGF-β superfamily is critically important for tissue development, repair, remodeling
and pathogenesis. Continuous crosstalk between TGF-β1 and the members of other signaling
pathways, such as activin A, together with factors produced in the tissue micromilieu, such as
pro- or anti-inflammatory cytokines, plays an important role in inflammation and remodeling
[11, 20]. The previous finding in white patients that CRSsNP is primarily a Th1 response,
whereas CRSwNP is associated with Th2 polarization [21], is consistent with the higher protein
concentrations of TGF-β1 and IFNγ and the lower concentrations of IL-5 and ECP in CRSsNP
compared with CRSwNP tissue homogenates in this study. However, further experiments will
be required to determine the molecular mechanism of cooperation between TGF-β1 and these
cytokines during airway inflammation and remodeling.
Activin A shares the same cytoplasmic Smad signaling pathway with TGF-β, but it also
binds to its own specific transmembrane receptors as well as to follistatin, a secreted protein
that inhibits activin by sequestration. Activin A was initially characterized as a reproductive
hormone but is now known to play many other roles. Similar to TGF-β1, activin A is a multi-
functional cytokine involved in the regulation of tissue remodeling and inflammation, as well
as tissue development and repair in various diseases, such as liver fibrosis, pancreatic fibrosis,
Fig 2. Protein expression of ECP, IL-5 and IFNγ in nasal tissue from CRSsNP (n = 13), CRSwNP
(n = 23) and Control patients (inferior turbinate) (n = 10). IFNγ protein expression was significantly higher
and IL-5 and ECP expression was significantly lower in CRSsNP compared with CRSwNP. Significance is
indicated by P value.
doi:10.1371/journal.pone.0128564.g002
Activin A and Follistatin in CRS
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Fig 3. Spontaneous release of activin A (A), Follistatin (B) and TGF-beta1 (C) in supernatants of nasal
tissue fragments from CRSsNP (n = 9) and CRSwNP patients (n = 7). The release of activin A (p = 0.015)
Activin A and Follistatin in CRS
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acute lung injury, asthma, and wound healing [13,14,22]. In a murine model of allergic asthma,
follistatin was preformed in the normal lung and then released together with activin A, suggest-
ing that it serves as an endogenous regulator [23]. In a recent study, intranasal follistatin inhib-
ited airway remodeling and decreased airway activin A and TGF-β1 levels in a dose-dependent
manner in an ovalbumin-sensitized mouse model [18]. These results demonstrate that follista-
tin attenuates asthmatic airway remodeling. In our previous studies, enhanced TGF-β1 signal-
ing in CRSsNP and decreased TGF-β1 signaling in CRSwNP were observed, indicating that
TGF-β1 is involved in the CRS remodeling process [4, 10]. However, activin A expression and
its link to TGF-β-dependent remodeling during CRS are not well understood. In this study, the
localization of activin A and follistatin in nasal tissues was identified by immunofluorescence
staining, with the epithelial layer been prominent for both molecules. Because the epithelial
barrier of CRSwNP has been demonstrated to be leaky [24], the release of these proteins from
the tissue through the epithelial barrier may be greater and quicker in CRSwNP vs. CRSsNP.
Different tissue remodeling patterns in CRSwNP vs. CRSsNP and the condition of the ECM,
impacting on the release of activated TGF-ß1 [25], may further contribute to the dissociation
of levels of activin A and follistatin between tissue homogenate protein measurements and
their spontaneous release into supernatants at 24 hours.
(Fig 3A) and follistatin (p = 0.005) (Fig 3B) was higher in CRSwNP than in CRSsNP subjects; in contrast, the
release of TGF-β1 (p = 0.036) (Fig 3C) was lower in CRSwNP than in CRSsNP at 24h. *P<0.05 compared to
1h and 4h.
doi:10.1371/journal.pone.0128564.g003
Fig 4. The ratios of Follistatin/ActivinA and Follistatin/TGF-beta1 in nasal tissue and supernatants. There was an imbalance between pro-fibrotic
(TGF-beta1, activin A) and anti-fibrotic (follistatin) mediators in CRSsNP (n = 9) and CRSwNP (n = 7). Statistical analysis was performed by using the
Wilcoxon test (for paired comparisons). Significance is indicated by P value.
doi:10.1371/journal.pone.0128564.g004
Activin A and Follistatin in CRS
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However, from the differences of the ratios of follistatin/activinA and follistatin/TGF-β1 in
tissues and supernatants in CRSsNP and CRSwNP, we can speculate that activin A is more ef-
fectively antagonized in CRSwNP than in CRSsNP and that there is an antagonistic effect be-
tween follistatin and TGF-β1. Lower activin A protein levels in the tissue homogenates from
CRSwNP patients is consistent with the findings from a previous study, in which local
Fig 5. The induction of activin A and TGF-β1 by one another in nasal tissue fragments from CRSsNP (n = 7) and control patients (inferior turbinate)
tissue (n = 7). The CRSsNP and control fragment suspensions were stimulated with TGF-β1 (0, 0.1, 1, 10 ng/mL) or Activin A (0, 1, 10, 100 ng/mL) for 24 h.
Activin A and TGF-β1 were tested in supernatants by ELISA. The figures show that activin A was induced by TGF-beta1 in CRSsNP and controls, but TGF-
ß1 was not induced by activin A. *p<0.05 compared to controls;$ p<0.05 compared to 0 ng/ml.
doi:10.1371/journal.pone.0128564.g005
Fig 6. CRSsNP and CRSwNP are two distinct disease entities with respect to remodeling patterns. The hypothesis was supported by the significantly
higher protein concentrations of activin A, follistatin, TGF-β1, and IFNγ and the lower concentrations of IL-5 and ECP, lower ratios of follistatin/activinA in
CRSsNP compared with CRSwNP tissue homogenates, in line with predominant fibrosis in CRSsNP and edema in CRSwNP.
doi:10.1371/journal.pone.0128564.g006
Activin A and Follistatin in CRS
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decreases in the expression of activin A were shown at sites exhibiting an abundance of B-cell
agglomerates in human nasal polyps [26].
The current study demonstrates, for the first time, an interaction between autocrine activin
A and TGF-β1 in CRSsNP tissue fragments. The enhancement of activin A secretion by TGF-
β1, leading to simultaneously increased expression for both molecules, suggests that activin A
and TGF-β1 synergistically promote CRSsNP fibrosis.
Limitations to this study include the lack of PCR data and signaling molecule study, howev-
er, we chose for the protein concentrations wherever possible, as RNA does not necessarily get
translated into protein, and protein normally is considered the parameter nearer to the actual
activity. Furthermore, we relied on historic measurements of fibrosis in the CRS group rather
than repeating those measurements in the current study [4, 10, 11]. However, we believe that
the new data we present are sufficient to appreciate the findings.
In summary, this study demonstrates a major imbalance in activin A and follistatin expres-
sion, similar to that of TGF-β1, in white patients with CRSwNP and CRSsNP. In addition,
higher levels of activin A were spontaneously released and its activity was enhanced by TGF-β1
in CRSsNP samples. Considering the observations made by other groups concerning the differ-
ential expression of key Th-cell cytokines (e.g., IFNγ and IL-5), these results support the hy-
pothesis that CRSsNP and CRSwNP are distinct disease entities. We also demonstrate that
activin A is linked to TGF-β1, and therefore also to remodeling, which is a key feature of
CRSsNP. In the network involving activin A and TGF-β1 regulation, activin A appears to be a
cooperative regulator and may act as a modulator of the balance between tissue integrity and
remodeling processes. A better understanding of the roles of activin A and TGF-β1 in airway
disease, as well as the influence of TGF superfamily members as a whole, may provide more
specific targets for treatment and prevention. However, specific details concerning the mecha-
nisms of interaction between activin A, TGF-β1 and other cytokines during CRS will require
further investigation. An ex-vivo study of the inhibitory effects of follistatin on activin A and
TGF-β1 in CRSsNP tissue and primary human sinonasal epithelial cells, and in vivo study of
the inhibitory effects on CRSsNP fibrosis are also warranted.
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